In the U.S., as many as 170,000 people are living with a group of bone marrow disorders called myelodysplastic syndromes (MDS), in which the body does not produce enough healthy blood cells.2
Low blood cell counts in people with MDS are responsible for common symptoms of the disease, including anemia and infections.2 People with MDS-related anemia often require regular blood transfusions to increase the number of healthy red blood cells in circulation.3
On October 20, 2020, leading up to MDS World Awareness Day on October 25, Dr. Caroline Behler of Pacific Hematology Oncology Associates, will be available to share more about a treatment option approved by the U.S. Food and Drug Administration (FDA) that may help reduce and eliminate frequent blood transfusions on adults living with MDS.4 Reblozyl® (luspatercept-aamt) (REB-loh-zil) is the first treatment in ten years to treat patients with this condition.1 Dr. Behler and Tracey Iraca, executive director at the MDS Foundation, together, will be available to discuss the challenges of managing the symptoms associated with a bone marrow cancer, like MDS, and where to find resources and support.
